Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Receivables (2021 - 2025)

Lucid Diagnostics' Receivables history spans 5 years, with the latest figure at $643000.0 for Q4 2025.

  • For Q4 2025, Receivables rose 1328.89% year-over-year to $643000.0; the TTM value through Dec 2025 reached $643000.0, up 1328.89%, while the annual FY2025 figure was $643000.0, 1328.89% up from the prior year.
  • Receivables reached $643000.0 in Q4 2025 per LUCD's latest filing, up from $550000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $10.7 million in Q2 2023 to a low of $21000.0 in Q3 2023.
  • Average Receivables over 5 years is $2.1 million, with a median of $373000.0 recorded in 2025.
  • Peak YoY movement for Receivables: soared 3220.5% in 2022, then plummeted 99.68% in 2023.
  • A 5-year view of Receivables shows it stood at $1.9 million in 2021, then soared by 168.01% to $5.0 million in 2022, then tumbled by 99.1% to $45000.0 in 2023, then changed by 0.0% to $45000.0 in 2024, then soared by 1328.89% to $643000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUCD's Receivables are $643000.0 (Q4 2025), $550000.0 (Q3 2025), and $373000.0 (Q2 2025).